Safety and effectiveness of fecal microbiota, live-jslm (REBYOTA <sup>®</sup> ) administered by colonoscopy for prevention of recurrent <i>Clostridioides difficile</i> infection: 8-week results from CDI-SCOPE, a single-arm, phase IIIb trial

Authors

W Knapple (ORCID: https://orcid.org/0009-0007-4081-3304)
Brian Baggott
Tahany Awad (ORCID: https://orcid.org/0000-0002-4766-9794)
Beth Guthmueller
David Yoho
Paul Feuerstadt (ORCID: https://orcid.org/0000-0002-7643-9576)
Sahil Khanna (ORCID: https://orcid.org/0000-0002-7619-8338)
Daniel Van Handel
Karen Simon
Brian J. Clark
Nasia Safdar (ORCID: https://orcid.org/0000-0003-3946-0437)
Daniel Armandi

Institutions

Cleveland Clinic (US)
Mayo Clinic (US)
University of Wisconsin–Madison (US)
Ferring Pharmaceuticals (United States) (US)
Ferring Pharmaceuticals (Denmark) (DK)
MNGI Digestive Health (US)
Gastroenterology Center of Connecticut (US)
Arkansas Department of Agriculture (US)

Publication Details

Journal: Therapeutic Advances in Gastroenterology
Published: 2025-04-22
DOI: https://doi.org/10.1177/17562848251339697
Citations: 4
Primary Topic: Clostridium difficile and Clostridium perfringens research
Type: article
Field-Weighted Citation Impact: 5.58

Funders

Ferring

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Safety and effectiveness of fecal microbiota, live-jslm (REBYOTA ^® ) administered by colonoscopy for prevention of recurrent Clostridioides difficile infection: 8-week results from CDI-SCOPE, a single-arm, phase IIIb trial

W Knapple, Brian Baggott, Tahany Awad, Beth Guthmueller et al.

Apr 22, 2025

4 citations

Therapeutic Advances in Gastroenterology

Clostridium difficile and Clostridium perfringens research

5.58

article

Safety and effectiveness of fecal microbiota, live-jslm (REBYOTA ^® ) administered by colonoscopy for prevention of recurrent Clostridioides difficile infection: 8-week results from CDI-SCOPE, a single-arm, phase IIIb trial

W Knapple, Brian Baggott, Tahany Awad, Beth Guthmueller, David Yoho, Paul Feuerstadt, Sahil Khanna, Daniel Van Handel, Karen Simon, Brian J. Clark, Nasia Safdar, Daniel Armandi

April 22, 2025article en

4 citations

Abstract

No abstract available for this paper.

Therapeutic Advances in GastroenterologyVol. 18

Cleveland Clinic (US), Mayo Clinic (US), University of Wisconsin–Madison (US), Ferring Pharmaceuticals (United States) (US), Ferring Pharmaceuticals (Denmark) (DK), MNGI Digestive Health (US), Gastroenterology Center of Connecticut (US), Arkansas Department of Agriculture (US)

Ferring

Openalex Percentile: Top 4%

Clostridium difficile and Clostridium perfringens research

5.58

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Safety and effectiveness of fecal microbiota, live-jslm (REBYOTA <sup>®</sup> ) administered by colonoscopy for prevention of recurrent <i>Clostridioides difficile</i> infection: 8-week results from CDI-SCOPE, a single-arm, phase IIIb trial — W Knapple, Brian Baggott, et al. · Therapeutic Advances in Gastroenterology (2025) | TGRS Research Map | TGRS